PT873340E - Compostos heterociclicos de ciclopentano substituido - Google Patents

Compostos heterociclicos de ciclopentano substituido

Info

Publication number
PT873340E
PT873340E PT96918151T PT96918151T PT873340E PT 873340 E PT873340 E PT 873340E PT 96918151 T PT96918151 T PT 96918151T PT 96918151 T PT96918151 T PT 96918151T PT 873340 E PT873340 E PT 873340E
Authority
PT
Portugal
Prior art keywords
cyclopentan
replaced
heterocyclic compounds
compounds
present
Prior art date
Application number
PT96918151T
Other languages
English (en)
Inventor
Shripad S Bhagwat
Marlon Daniel Cowart
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PT873340E publication Critical patent/PT873340E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT96918151T 1995-06-07 1996-06-06 Compostos heterociclicos de ciclopentano substituido PT873340E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47248695A 1995-06-07 1995-06-07
US08/651,882 US6143749A (en) 1995-06-07 1996-06-04 Heterocyclic substituted cyclopentane compounds

Publications (1)

Publication Number Publication Date
PT873340E true PT873340E (pt) 2002-05-31

Family

ID=27043790

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96918151T PT873340E (pt) 1995-06-07 1996-06-06 Compostos heterociclicos de ciclopentano substituido

Country Status (11)

Country Link
US (1) US6143749A (pt)
EP (1) EP0873340B1 (pt)
JP (1) JP2000501694A (pt)
AT (1) ATE209206T1 (pt)
CA (1) CA2220006A1 (pt)
DE (1) DE69617273T2 (pt)
DK (1) DK0873340T3 (pt)
ES (1) ES2168479T3 (pt)
MX (1) MX9709718A (pt)
PT (1) PT873340E (pt)
WO (1) WO1996040686A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674998A (en) * 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5721356A (en) * 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
CH690773A5 (de) * 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9704948D0 (en) 1997-03-11 1997-04-30 Knoll Ag Therapeutic agents
KR20000076426A (ko) * 1997-03-19 2000-12-26 스타르크, 카르크 피롤로[2,3-ｄ]피리미딘 및 티로신 키나제 저해제로서의 그의 용도
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
AU7108398A (en) * 1997-04-16 1998-11-11 Abbott Laboratories 5,7-disubstituted 4-aminopyrido{2,3-d}pyrimidine compounds and their use as adenosine kinase inhibitors
JP2002526500A (ja) * 1998-09-18 2002-08-20 ビーエーエスエフ アクチェンゲゼルシャフト プロテインキナーゼ阻害剤としてのピロロピリミジン
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
AU2000240570A1 (en) * 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
GB0128885D0 (en) * 2001-12-03 2002-01-23 Merck Sharp & Dohme Therapeutic agents
CA2543116A1 (en) * 2003-10-27 2005-05-19 Genelabs Technologies, Inc. Methods for preparing 7-(2'-substituted-.szlig.-d-ribofuranosyl)-4-(nr2r3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
US7345034B2 (en) * 2004-04-07 2008-03-18 Abbott Laboratories Azacyclosteroid histamine-3 receptor ligands
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
WO2007087395A2 (en) * 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
ES2440317T3 (es) * 2006-04-21 2014-01-28 Novartis Ag Derivados de purina para su uso como agonistas del receptor de adenosina A2A
BRPI0819799A2 (pt) * 2007-11-23 2015-05-26 Leo Pharma As Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
GB201004311D0 (en) * 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
GB201115853D0 (en) * 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
SG11201400277VA (en) * 2011-09-14 2014-05-29 Proximagen Ltd New enzyme inhibitor compounds
US9682083B2 (en) 2013-05-14 2017-06-20 Nerviano Medical Sciences S.R.L. Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
TWI730980B (zh) 2015-08-26 2021-06-21 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
MA41559A (fr) 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
PT3269370T (pt) 2016-02-23 2020-03-05 Taiho Pharmaceutical Co Ltd Novo composto de pirimidina condensada ou sal do mesmo
UA123637C2 (uk) 2016-03-10 2021-05-05 Янссен Фармацевтика Нв Заміщені аналоги нуклеозидів для застосування як інгібіторів prmt5
CA2969295A1 (en) * 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
MX2019002959A (es) 2016-09-14 2019-07-04 Janssen Pharmaceutica Nv Inhibidores biciclicos condensados de la interaccion de menina-mll.
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
ES2872003T3 (es) 2016-09-14 2021-11-02 Janssen Pharmaceutica Nv Inhibidores espirobicíclicos de la interacción de menina-MLL
CN115626935A (zh) * 2016-10-03 2023-01-20 詹森药业有限公司 用作prmt5抑制剂的单环和双环系统取代的卡巴核苷类似物
BR112019012106A2 (pt) 2016-12-15 2019-10-29 Janssen Pharmaceutica Nv inibidores de azepano de interação menin-mill
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
JP7225106B2 (ja) 2017-02-27 2023-02-20 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用
WO2018160824A1 (en) * 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2019110734A1 (en) * 2017-12-08 2019-06-13 Janssen Pharmaceutica Nv Novel spirobicyclic analogues
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
WO2020198323A1 (en) * 2019-03-25 2020-10-01 California Institute Of Technology Prmt5 inhibitors and uses thereof
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
PE20220433A1 (es) 2019-06-12 2022-03-29 Janssen Pharmaceutica Nv Intermedios espirobiciclicos novedosos
CN111320634A (zh) * 2020-04-14 2020-06-23 浙江工业大学 一种乙酰氧取代的吡咯并[2,3-d]嘧啶衍生物的制备方法
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3551428A (en) * 1956-02-10 1970-12-29 Ciba Geigy Corp New 1- (or 2-) substituted 4-mercapto-pyrazolo(3,4-d)pyrimidines
US3311628A (en) * 1965-03-09 1967-03-28 Bristol Myers Co Derivatives of pyrrolo [2, 3-d] pyrimidine
US3296261A (en) * 1965-03-09 1967-01-03 Bristol Myers Co 6-hydroxy-pyrimidine-5-acetamides
US5223618A (en) * 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
CA2100863A1 (en) * 1991-01-23 1992-07-24 David A. Bullough Adenosine kinase inhibitors
EP0521463A3 (en) * 1991-07-04 1993-04-14 Hoechst Aktiengesellschaft Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents
WO1994006438A1 (en) * 1992-09-11 1994-03-31 The Regents Of The University Of California Adenosine analogues and method of increasing adenosine release
DK0674641T3 (da) * 1992-12-17 1999-09-27 Pfizer Pyrrolopyrimidiner som CRF-antagonister
EP0684953A4 (en) * 1993-02-03 1999-12-22 Gensia Inc ADENOSINE KINASE INHIBITORS COMPRISING LYXOFURANOSYL DERIVATIVES.
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain

Also Published As

Publication number Publication date
DE69617273T2 (de) 2002-07-25
EP0873340A1 (en) 1998-10-28
WO1996040686A1 (en) 1996-12-19
JP2000501694A (ja) 2000-02-15
DK0873340T3 (da) 2002-05-21
US6143749A (en) 2000-11-07
DE69617273D1 (de) 2002-01-03
ES2168479T3 (es) 2002-06-16
MX9709718A (es) 1998-07-31
ATE209206T1 (de) 2001-12-15
CA2220006A1 (en) 1996-12-19
EP0873340B1 (en) 2001-11-21

Similar Documents

Publication Publication Date Title
PT873340E (pt) Compostos heterociclicos de ciclopentano substituido
FI941580A (fi) Bisyklisiä ansamysiinejä
ES2172657T3 (es) Inhibidores de trombina.
ATE267200T1 (de) Bicyclische kinase inhibitoren
PE41395A1 (es) Antagonista de taquiquinina no peptidico
DE69528528D1 (de) Thrombin-inhibitoren
MX9707431A (es) Inhibidores de la proteina cinasa c.
TR199800759T2 (xx) Protein Kinaz C �nhibit�r�.
ATE217865T1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
DK0705100T3 (da) Terapeutiske substituerede guanidiner
DK0657458T3 (da) Inhibitorer af proteinkinase-C
ID27535A (id) Turunan pirasola sebagai inhibitor p-38 map kinase
DE60142921D1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
EA199900837A1 (ru) Способ применения ингибиторов циклооксигеназы-2 для предупреждения сердечно-сосудистых расстройств
TR200101756T2 (tr) Protein kinaz inhibitörleri olarak 4,5-pirazinoksindoller.
PT1282418E (pt) Utilizacao de derivados pirazolo para o tratamento da infertilidade
GEP20084346B (en) Protein kinase c inhibitors
ATE293964T1 (de) Zusammensetzungen und verfahren zur behinderung der entladung von nematokyste
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
EA200000522A1 (ru) 5-htагонисты
AR028186A1 (es) Compuestos de 5-aril-1, 2, 4-triazol inhibidores de ciclooxigenasa-2 y composiciones farmaceuticas que comprenden dichos compuestos